HEREDITARY HEMORRHAGIC TELANGIECTASIA
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug shows promise for rare bleeding disorder
Disease control OngoingThis phase 2 trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal blood vessels that bleed easily. The study involves 33 adul…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
Disease control OngoingThis study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researc…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused OngoingThis study is creating a registry of people with Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessels and frequent nosebleeds. Researchers will collect health information from about 1,000 adults over many years to see how the disease ch…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC